Ann: Phosphagenics Announces Results of TPM/Oxycodone Ph2a Trial, page-53

Paul Gavin is very persuasive, always has been. Talks well and is quite interesting actually. But the reality is this trial failed its primary endpoint and how long has it taken to get to this trial. Back to the drawing board and possibly another year or two delay. Share price .7c now, many have already decided not to wait any more. Quite sad really what's happened to this once very prospective company. But it's the reality of biochemical researchers, its a very speculative area, time-consuming and expensive.